Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma
Claudia Perrera(Nerviano Medical Sciences), Barbara Valsasina(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Laura Mancini(University College London), Simona Bindi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Maurizio Pulici(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Daniela Asa(Nerviano Medical Sciences), Patrizia Banfi(Nerviano Medical Sciences), Elena Ardini(Nerviano Medical Sciences), Elena Casale, Eduard Felder, Fabio Gasparri(Nerviano Medical Sciences), Daniele Casero(Nerviano Medical Sciences), Stefania Re Depaolini(Nerviano Medical Sciences), Fulvia Roletto(Nerviano Medical Sciences), Ilaria Motto(Nerviano Medical Sciences), Davide Carenzi(Nerviano Medical Sciences), Simona Rizzi(Nerviano Medical Sciences), Sabrina Cribioli(Nerviano Medical Sciences), Marina Fasolini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 1
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205